Program
Lithium Carbonate
Also written as “lithium carbonate”, “Lithium carbonate” and “Lithium Carbonate Capsule”.
Its studies are mostly in Depressive Disorder, Major · Bipolar Disorder, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 10 open or running | phase 3since Nov 11, 2008 | Nov 11, 2008 | none ahead |
| Columbia Northwest Pharmaceuticals | 10 open or running | phase 2since Mar 18, 2010 | Mar 18, 2010 | none ahead |
| Eli Lilly | 10 open or running | phase 3since Jun 11, 2007 | Jun 11, 2007 | none ahead |
| JDS Pharmaceuticals | 10 open or running | phase 3since Jan 11, 2007 | Jan 11, 2007 | none ahead |
| Merck | 10 open or running | phase 1since Dec 2, 2024 | Dec 2, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 11, 2007First study: phase 3 study in Bipolar DisorderNew to JDS PharmaceuticalsJDS Pharmaceuticals · NCT00422331 · 206 enrolled · United States
- Jun 11, 2007Eli Lilly's first study: phase 3 study in Bipolar DisorderNew to Eli LillyEli Lilly · NCT00485680 · 140 enrolled · China
- Nov 11, 2008AstraZeneca's first study: phase 3 study in Depressive Disorder, MajorNew to AstraZenecaAstraZeneca · NCT00789854 · 688 enrolled · Australia, Austria, Belgium and more
- Mar 18, 2010Columbia Northwest Pharmaceuticals's first study: phase 2 study in Depressive Disorder, MajorNew to Columbia Northwest PharmaceuticalsColumbia Northwest Pharmaceuticals · NCT01189812 · 80 enrolled · United States
- Dec 2, 2024Merck's first study: phase 1 study in HealthyNew to MerckMerck · NCT06719544 · 16 enrolled · United States
TargetBeta
“Inositol-1(or 4)-monophosphatase 1 inhibitor; Glycogen synthase kinase-3 inhibitor”ChEMBL 37, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06719544Healthy · United States | 1 | Completed | Merck | Jan 27, 2025 | 16 |
| NCT01189812Depressive Disorder, Major · United States | 2 | Completed | Columbia Northwest Pharmaceuticals | Jan 2011 | 80 |
| NCT00789854Depressive Disorder, Major · Australia, Austria, Belgium and more | 3 | Completed | AstraZeneca | Aug 2009 | 688 |
| NCT00485680Bipolar Disorder · China | 3 | Completed | Eli Lilly | 140 | |
| NCT00422331Bipolar Disorder · United States | 3 | UNKNOWN | JDS Pharmaceuticals | 206 |
How it is read
Names in the registry
- “Lithium Carbonate”, 2 entries
- “lithium carbonate”, 1 entry
- “Lithium carbonate”, 1 entry
- “Lithium Carbonate Capsule”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 2 studies
- Bipolar Disorder, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.